| Cat. No. |
Product Name |
CAS No. |
Information |
| H8994 |
DMI 9523
|
397847-46-0 |
DMI 9523 is a nuclear factor NF-κB activation inhibitor. DMI 9523 is a naturally occurring anti-inflammatory compound that is under development for the treatment of osteoarthritis of the knee. |
| H5630 |
Withaferin A
|
5119-48-2 |
Withaferin A is a steroid lactone that displays anti-inflammatory, antitumor and antiangiogenic activity, potently inhibits NF-κB activation by preventing the TNF-induced activation of IKKβ via a thioalkylation-sensitive redox mechanism; potently inhibits the chymotrypsin-like activity of a purified rabbit 20S proteasome (IC50=4.5 uM) and 26S proteasome in human prostate cancer cultures (at 5-10 uM) and xenografts (4-8 mg/kg/day), inhibits cell proliferation in HUVECs (IC50 =12 nM). |
| H5629 |
SR12460
|
2055101-66-9 |
SR12460 (SR-12460) is a novel NF-κB essential modulator (NEMO)-binding domain (NBD) mimetic for inhibiting IKK/NF-κB activation, inhibits TNF-α-mediated NF-κB activation with IC50 of 20.24 uM; inhibits lipopolysaccharide (LPS)-induced NF-κB activation by blocking the interaction between IKKβ and NEMO and suppressed LPS-induced acute pulmonary inflammation in mice without overt liver toxicity. |
| H5628 |
SR12343
|
2055101-86-3 |
SR12343 (SR-12343) is a novel NF-κB essential modulator (NEMO)-binding domain (NBD) mimetic for inhibiting IKK/NF-κB activation, inhibits TNF-α-mediated NF-κB activation with IC50 of 11.34 uM in luciferase assays; inhibits lipopolysaccharide (LPS)-induced NF-κB activation by blocking the interaction between IKKβ and NEMO, significantly inhibits COX-2, IL-6, and iNOS expression at 50 uM in cellular assays; suppresses LPS-induced acute pulmonary inflammation, alleviates necrosis and muscle degeneration in mdx mice without overt liver toxicity. |
| H5627 |
SEMBL
|
1443448-82-5 |
SEMBL is a potent NF-κB inhibitor that inhibits DNA binding of NF-κB component p65; inhibits LPS-induced NF-κB activation, iNOS expression, and inflammatory cytokine secretions; also inhibits NF-κB and cellular invasion in ovarian carcinoma ES-2 cells; enhances stability in aqueous solution compared with (-)-DHMEQ. |
| H5626 |
NDMC101
|
1308631-40-4 |
A small molecule that inhibits NFATc1 and NF-κB activity, inhibits RANKL-induced osteoclastogenesis in vivo; markedly inhibits RANKL-induced formation of TRAP+ multinucleated cells in RAW264.7 and bone marrow macrophage cells (BMMs); significantly reduces the bone-resorbing activity of mature osteoclasts; reduces arthritic index and mitigated bone erosion in CIA mice. |
| H5625 |
Lipoic acid
|
1200-22-2 |
A multifunction antioxidant that has growth promoting, anti-inflammatory, antioxidative, immunostimulatory, and hypocholesterolemic properties. |
| H5624 |
IT-901
|
1584121-99-2 |
IT-901 is a novel potent, small molecule inhibitor of NF-κB subunit c-Rel, inhibits DNA binding of c-Rel and NF-κB activity with IC50 of 3 uM; reduces stimulation of the oxidative stress response gene heme oxygenase-1, inhibits c-Rel/NF-κB both in vitro and in vivo. |
| H5623 |
IT-603
|
292168-90-2 |
A small molecule inhibitor of the NF-κB family member c-Rel with IC50 of 3 uM in EMSA assays; inhibits human diffuse large B-cell lymphoma (DLBCL) cell line with IC50 of 18 uM, binds c-Rel directly and changes the conformation of the protein, inhibiting DNA binding and transcriptional activity. |
| H5622 |
Iguratimod
|
123663-49-0 |
A novel disease-modifying antirheumatic drug that inhibits NF-kappaB (NF-κB) p65 subunit (RelA) phosphorylation and nuclear translocation without affecting IKBα degradation; inhibits LPS-stimulated production of TNF-α, IL-6, and IL-8 with decreasing mRNA levels (IL-6 and IL-8); mainly targets Act1 to disrupt the interaction between Act1 and TRAF5 and IKKi in the IL-17 pathway of synoviocytes; also exhibts selective MIF inhibition in vitro and in vivo. |
$ USD
Select Your Country or Region